Related Experiment Video
Updated: Jun 11, 2026
11:19
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy
1Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, CA 94609, USA. mwmedina@chori.org
Discovery Medicine
|July 1, 2010
Summary
Statins effectively lower cholesterol but vary in efficacy. Genetic studies reveal that 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) alternative splicing influences statin effectiveness for cardiovascular disease and colorectal cancer prevention.
Area of Science:
- Pharmacogenetics
- Molecular Biology
- Cardiovascular Medicine
Background:
- Statins inhibit HMGCR, a key enzyme in cholesterol biosynthesis.
- Individual responses to statins vary significantly in lowering LDL-cholesterol.
- Genetic variations in HMGCR are linked to this inter-individual response variability.
Purpose of the Study:
- To investigate the role of HMGCR genetic variation in statin efficacy.
- To determine if HMGCR alternative splicing is a determinant of statin response.
- To explore the implications for hypercholesterolemia treatment and colorectal cancer chemoprevention.
Main Methods:
- Pharmacogenetic analysis of HMGCR genetic variation.
- Investigation of HMGCR alternative splicing, specifically exon 13.
- Correlation of splicing patterns with statin efficacy in clinical outcomes.
Main Results:
- HMGCR alternative splicing of exon 13 was identified as a key factor in statin efficacy.
- This splicing variation is not merely a marker but directly influences treatment outcomes.
- The findings apply to both cholesterol reduction and cancer chemoprevention.
Conclusions:
- HMGCR alternative splicing of exon 13 is a critical determinant of statin efficacy.
- Understanding this mechanism can personalize statin therapy for hypercholesterolemia.
- Targeting HMGCR splicing may offer new avenues for colorectal cancer chemoprevention.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...